It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In Parkinson’s disease and other synucleinopathies, the elevation of α-synuclein phosphorylated at Serine129 (pS129) is a widely cited marker of pathology. However, the physiological role for pS129 has remained undefined. Here we use multiple approaches to show for the first time that pS129 functions as a physiological regulator of neuronal activity. Neuronal activity triggers a sustained increase of pS129 in cultured neurons (200% within 4 h). In accord, brain pS129 is elevated in environmentally enriched mice exhibiting enhanced long-term potentiation. Activity-dependent α-synuclein phosphorylation is S129-specific, reversible, confers no cytotoxicity, and accumulates at synapsin-containing presynaptic boutons. Mechanistically, our findings are consistent with a model in which neuronal stimulation enhances Plk2 kinase activity via a calcium/calcineurin pathway to counteract PP2A phosphatase activity for efficient phosphorylation of membrane-bound α-synuclein. Patch clamping of rat SNCA−/− neurons expressing exogenous wild-type or phospho-incompetent (S129A) α-synuclein suggests that pS129 fine-tunes the balance between excitatory and inhibitory neuronal currents. Consistently, our novel S129A knock-in (S129AKI) mice exhibit impaired hippocampal plasticity. The discovery of a key physiological function for pS129 has implications for understanding the role of α-synuclein in neurotransmission and adds nuance to the interpretation of pS129 as a synucleinopathy biomarker.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Brigham and Women’s Hospital and Harvard Medical School, Ann Romney Center for Neurologic Diseases, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
2 Leveragen, Inc., Worcester, USA (GRID:grid.38142.3c)
3 University College London, UK Dementia Research Institute, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
4 New York State Psychiatric Institute, Research Foundation for Mental Hygiene, Division of Molecular Therapeutics, New York, USA (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112)
5 New York State Psychiatric Institute, Research Foundation for Mental Hygiene, Division of Molecular Therapeutics, New York, USA (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112); Columbia University Medical Center, Departments of Neurology and Psychiatry, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Medical Center, Department of Molecular Therapeutics and Pharmacology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
6 New York State Psychiatric Institute, Research Foundation for Mental Hygiene, Division of Molecular Therapeutics, New York, USA (GRID:grid.413734.6) (ISNI:0000 0000 8499 1112); Columbia University Medical Center, Departments of Neurology and Psychiatry, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
7 Leveragen, Inc., Worcester, USA (GRID:grid.239585.0)